In direct compression lines running at sustained press speeds above 40 rpm, the physical heterogeneity of L-arginine-L-aspartate—low bulk density, angular crystal habit, and moisture uptake above 60% relative humidity—creates die-fill variability that cannot be corrected solely by feed-frame paddle adjustment. For a target 1000 mg arginine-equivalent tablet, the salt stoichiometry of the 1:1 molar form requires 1.76 g L-arginine-L-aspartate per unit by mass, because arginine base contributes 174.2 g/mol of the 307.3 g/mol salt. A core compressed at total mass 2500 mg therefore places the active at 70.4% w/w; the remaining 29.6% w/w is partitioned among microcrystalline cellulose, crospovidone, colloidal silicon dioxide, and magnesium stearate. The downstream process is roller compaction followed by oscillating mill screening to a granule D50 of 200–350 µm, then rotary compression with a feed frame paddle speed reduced to avoid particle attrition. In production-scale campaigns, film-coated tablets are tested against USP <905> for content uniformity, USP <711> for dissolution, and Ph. Eur. 2.9.5/2.9.3 where dual-market release is required. Terminal product types include immediate-release film-coated tablets at 500 mg, 750 mg, and 1000 mg arginine-equivalent strengths. Because published data for direct compression of this specific aspartate crystal are limited, a roller-compacted placebo-blend feasibility run should be completed before locking batch records.

What Changes When L-Arginine-L-Aspartate Enters a Hard Capsule Filling Line?

Hard capsule filling of the aspartate salt is governed less by dissolution than by bulk-powder transport, because its cohesive character and low tap density commonly result in powder bridging inside dosator tubes on automatic capsule machines. A single unit delivering 500 mg arginine requires 0.88 g of the 1:1 salt; the choice between size 00 and 000 HPMC capsules then depends on the tapped density of the densified granule rather than on salt solubility alone. A densified fill framework places L-arginine-L-aspartate granule at 40–60% w/w, dibasic calcium phosphate anhydrous at 30–45% w/w, croscarmellose sodium at 2–5% w/w, and magnesium stearate at 0.5–1.0% w/w. The production process uses a tamping-pin or dosator capsule filler operated at reduced disc speed; in-line checkweighing at ±3% of target fill mass rejects partially filled units, while capsule shell loss on drying is maintained below 8.0% to prevent shell brittleness. Compliance for the finished capsule includes USP <905> for uniformity of dosage units, USP <711> for dissolution, and USP <701> for disintegration; for EU submission, Ph. Eur. 2.9.5 and 2.9.3 are applied in parallel. Terminal product types are hard HPMC capsules and, where moisture protection is critical, blister-pack units with polyvinyl chloride-polychlorotrifluoroethylene laminates at 500 mg and 750 mg arginine-equivalent strengths.

Because the salt exhibits measurable moisture uptake at relative humidity above 60% and can become pasty when aqueous binder is applied at high spray rates, fluidized-bed granulation for sachet-grade material is operated with conservative inlet-air dew point control. A unit-dose sachet delivering 3.0 g arginine equivalent contains 5.28 g L-arginine-L-aspartate; if the finished fill weight is fixed at 8.0 g, the active load is 66.0% w/w, with the remaining 34.0% w/w composed of mannitol, povidone K30, citric acid, and silicon dioxide. The top-spray fluid-bed process runs at inlet air 50–60°C and product bed 30–36°C; spray rate is reduced until granule moisture remains below 2.0% by Karl Fischer titration. Finished granules are sieved to 200–800 µm and filled into stick packs under dry air at ≤20% relative humidity. Compliance for the granule includes USP <786> for particle size distribution, USP <921> for water content, and Ph. Eur. 2.9.12 where a European dossier is required. Terminal product types are oral granules in stick packs, sachets, and multi-dose reconstitutable powder containers labeled for reconstitution before administration.

When Terminal Steam Sterilization Is Mandatory for an Injectable Administration Form

Injectable formulations containing L-arginine-L-aspartate require terminal heat exposure windows that are established against both chemical stability and subvisible particle growth, because the salt can contribute to pH drift and container surface interaction under vapor-phase steam cycles. For a low-concentration infusion containing 1.0% w/v arginine equivalent, the dissolved salt concentration is 1.76% w/v; at 2.0% w/v arginine equivalent, the salt concentration is 3.52% w/v, calculated from the 174.2 g/mol arginine base fraction in the 307.3 g/mol salt. The solution is compounded in Water for Injection at 20–25°C, sparged with nitrogen to keep dissolved oxygen below 0.5 mg/L, adjusted to pH 5.0–6.0 if necessary, and passed through 0.22 µm sterilizing-grade filtration before autoclaving at 121°C for 15 min. Release testing follows USP <1> injections, USP <71> sterility, USP <85> bacterial endotoxin, USP <788> particulate matter, and USP <790> visible particulates; for EU filings, Ph. Eur. 2.6.1, 2.6.14, and 2.9.19 apply. Production-scale filling is performed on a blow-fill-seal or vial line with 100% vision inspection, because glass ampoule tip breaks may introduce particulates if flame sealing is not controlled. Terminal product types are sterile single-dose ampoules and vials intended for intravenous administration after dilution, with arginine-equivalent concentrations of 1.0 g/100 mL and 2.0 g/100 mL. Published stability data for terminal steam sterilization of this specific salt form remain limited; a post-autoclave purity assay should be coupled with pH and osmolality monitoring at each cycle qualification.

Lyophilized dosage forms containing L-arginine-L-aspartate commonly fail at the cake-structure stage rather than in the freeze-drying chamber itself, because the soluble salt can depress the frozen-phase glass transition temperature and produce microcollapse when primary drying is accelerated prematurely. A lyophilization formulation prepared for intramuscular or intravenous reconstitution may contain 80–90% w/w L-arginine-L-aspartate in the solid fraction, with mannitol or trehalose at 10–20% w/w as the crystalline bulking component; the total pre-lyophilization solution is typically adjusted to pH 5.5–6.5. The cycle begins with freezing at -45°C for not less than 120 min, followed by primary drying at shelf temperature -25°C and chamber pressure 0.2–0.3 mbar, with secondary drying ramped to 35°C for at least 6 h to reduce residual moisture below 1.0%. Process analytical inspection includes cake appearance, reconstitution time below 60 s, and subvisible particulate counts under Ph. Eur. 2.9.19 and USP <788> after reconstitution with sterile water. Finished product types are lyophilized plugs in Type I glass vials at 500 mg and 1000 mg arginine-equivalent strengths, closed with bromobutyl rubber stoppers. Published freeze-drying characterization for this specific aspartate salt is limited; collapse temperature determination by freeze-drying microscopy is advised before cycle scale-up.

Parenteral Amino Acid Compounding and the Role of L-Arginine-L-Aspartate in Centralized Admixture Services

Compounding with L-arginine-L-aspartate in centralized intravenous admixture units shifts the compatibility assessment from simple amino acid solubility to calcium-phosphate stability, because the aspartate anion may lower solution pH and reduce the risk of dibasic calcium phosphate precipitation, yet the inherent acid load requires verification against the prescribed acetate or chloride balance. When a parenteral nutrition order specifies arginine base at 2.0 g/L, the corresponding salt quantity is 3.52 g/L; at 5.0 g/L arginine base, the salt quantity is 8.8 g/L. Compounding is performed in an ISO Class 5 laminar airflow workbench under USP <797> pharmaceutical compounding—sterile preparations, with filter sterilization using a 0.22 µm inline membrane and final visual inspection for precipitation using high-intensity spot lighting. Compatibility is rechecked for calcium gluconate and sodium glycerophosphate additions; published data for this specific aspartate salt in multi-chamber bag combinations remain limited, so a small-scale admixture challenge is performed at the upper calcium and phosphate limits before batch compounding. Terminal product types are patient-specific parenteral amino acid infusion bags, concentrated amino acid bulk solutions for automated compounders, and central-line-ready configurations labeled with the osmolarity measured after admixture.